Chapter 4: Pharmacogenetics & Personalized Drug Therapy

By analyzing how hereditary factors impact individual drug responses, healthcare providers can utilize personalized medicine to optimize therapeutic outcomes and minimize the high rates of treatment failure and adverse drug reactions that frequently burden the healthcare system. The narrative traces the evolution of genetic science from Mendelian inheritance and the discovery of the DNA double helix to the completion of the Human Genome Project and the modern Precision Medicine Initiative. Key concepts are defined, including the roles of alleles, genotypes, and phenotypes, while categorizing patients into metabolic groups such as poor, intermediate, extensive, or ultrarapid metabolizers. These classifications are vital for managing drugs with narrow therapeutic windows or those requiring enzymatic activation, such as the anticoagulant warfarin, the antiplatelet clopidogrel, and prodrug opioids like codeine and tramadol. Furthermore, the chapter details the essential nursing implications of pharmacogenetic technology, emphasizing the importance of assessing multi-generational family histories, identifying potential genetic-based hypersensitivity risks (such as those associated with abacavir or carbamazepine), and providing patient advocacy. Ethical and legal dimensions are also addressed, specifically focusing on patient autonomy, the Right Drug Dose Now Act, and the protections and limitations of the Genetic Information Nondiscrimination Act (GINA) in preventing genetic-based discrimination by employers and health insurers.